1. Home
  2. TBLA vs CRVS Comparison

TBLA vs CRVS Comparison

Compare TBLA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$3.50

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$11.71

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBLA
CRVS
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
TBLA
CRVS
Price
$3.50
$11.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$5.00
★ $30.17
AVG Volume (30 Days)
★ 1.8M
861.2K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1400.00
48.04
EPS
★ 220.00
N/A
Revenue
★ $1,912,040,000.00
N/A
Revenue This Year
$7.63
N/A
Revenue Next Year
$5.25
N/A
P/E Ratio
$0.02
★ N/A
Revenue Growth
★ 8.26
N/A
52 Week Low
$2.84
$6.39
52 Week High
$5.71
$26.95

Technical Indicators

Market Signals
Indicator
TBLA
CRVS
Relative Strength Index (RSI) 34.68 34.36
Support Level $2.97 $11.13
Resistance Level $3.94 $14.00
Average True Range (ATR) 0.12 0.70
MACD -0.01 -0.13
Stochastic Oscillator 20.87 9.12

Price Performance

Historical Comparison
TBLA
CRVS

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: